Literature DB >> 11524717

Quinolone molecular structure-activity relationships: what we have learned about improving antimicrobial activity.

L R Peterson1.   

Abstract

Recently, understanding of how molecular modifications of the core quinolone structure affect(s) antimicrobial agent activity has progressed rapidly. Three positions (2, 3, and 4) cannot be changed without a significant loss of biological activity. Furthermore, it appears that a cyclopropyl group is optimal at position 1. Substituents at positions 5 and 8 affect planar configuration, and either a methyl or methoxy appear optimal at these sites. Hydrogen and amino groups have been investigated as useful substituents at position 6, replacing the fluorine of the fluoroquinolones. Interestingly, in vitro activity enhancement observed with alterations at positions 5 and 6 is not always accompanied by improved in vivo action. For all these modifications, the substituents at positions 7 and 8 are critical for potent antimicrobial activity. Optimizing overall molecular configuration enhances the number of intracellular targets for antimicrobial action (R-8) and impedes the efficiency of efflux proteins (R-7) that diminish intracellular penetration.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11524717     DOI: 10.1086/321846

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  28 in total

1.  Combinatorially-generated library of 6-fluoroquinolone analogs as potential novel antitubercular agents: a chemometric and molecular modeling assessment.

Authors:  Nikola Minovski; Andrej Perdih; Tom Solmajer
Journal:  J Mol Model       Date:  2011-08-12       Impact factor: 1.810

Review 2.  In front of and behind the replication fork: bacterial type IIA topoisomerases.

Authors:  Claudia Sissi; Manlio Palumbo
Journal:  Cell Mol Life Sci       Date:  2010-02-18       Impact factor: 9.261

3.  In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.

Authors:  Heather J Adam; Nancy M Laing; C Richard King; Ben Lulashnyk; Daryl J Hoban; George G Zhanel
Journal:  Antimicrob Agents Chemother       Date:  2009-09-08       Impact factor: 5.191

Review 4.  Antibiotic Hybrids: the Next Generation of Agents and Adjuvants against Gram-Negative Pathogens?

Authors:  Ronald Domalaon; Temilolu Idowu; George G Zhanel; Frank Schweizer
Journal:  Clin Microbiol Rev       Date:  2018-03-14       Impact factor: 26.132

5.  Quantitative structure-activity relationship study of antitubercular fluoroquinolones.

Authors:  Nikola Minovski; Marjan Vračko; Tom Solmajer
Journal:  Mol Divers       Date:  2010-03-14       Impact factor: 2.943

6.  Fluoroquinolone resistance is a poor surrogate marker for type II topoisomerase mutations in clinical isolates of Streptococcus pneumoniae.

Authors:  J J Millichap; E Pestova; F Siddiqui; G A Noskin; L R Peterson
Journal:  J Clin Microbiol       Date:  2001-07       Impact factor: 5.948

7.  In vitro activities of novel nonfluorinated quinolones PGE 9262932 and PGE 9509924 against clinical isolates of Staphylococcus aureus and Streptococcus pneumoniae with defined mutations in DNA gyrase and topoisomerase IV.

Authors:  Mark E Jones; Ian A Critchley; James A Karlowsky; Renée S Blosser-Middleton; Franz-Josef Schmitz; Clyde Thornsberry; Daniel F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

8.  Dual targeting of topoisomerase IV and gyrase to reduce mutant selection: direct testing of the paradigm by using WCK-1734, a new fluoroquinolone, and ciprofloxacin.

Authors:  Jacob Strahilevitz; David C Hooper
Journal:  Antimicrob Agents Chemother       Date:  2005-05       Impact factor: 5.191

9.  Topoisomerase targeting with and resistance to gemifloxacin in Staphylococcus aureus.

Authors:  Dilek Ince; Xiamei Zhang; L Christine Silver; David C Hooper
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

Review 10.  Maintaining fluoroquinolone class efficacy: review of influencing factors.

Authors:  W Michael Scheld
Journal:  Emerg Infect Dis       Date:  2003-01       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.